90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma
Targeted radioimmunotherapy with 90Y-labeled ibritumomab tiuxetan is a novel therapeutic
approach for CD20-positive relapsed or refractory non-Hodgkin lymphoma (NHL). Methods …
approach for CD20-positive relapsed or refractory non-Hodgkin lymphoma (NHL). Methods …
Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's …
IF Khouri, RM Saliba, C Hosing, R Valverde, WD Erwin… - 2006 - ashpublications.org
Background: Relapse continues to be the primary cause of treatment failure in patients with
NHL undergoing stem-cell transplantation (SCT). The anti-CD20 radioimmunoconjugate …
NHL undergoing stem-cell transplantation (SCT). The anti-CD20 radioimmunoconjugate …
High-dose yttrium-90–ibritumomab tiuxetan with tandem stem-cell reinfusion: An outpatient preparative regimen for autologous hematopoietic cell transplantation
Purpose To develop high-dose myeloablative therapy for CD20+ non-Hodgkin's lymphoma
(NHL) as a safe and widely applicable regimen. Patients and Methods Patients with …
(NHL) as a safe and widely applicable regimen. Patients and Methods Patients with …
Experience with yttrium 90 ibritumomab tiuxetan after autologous stem cell transplant (ASCT) in patients with non-Hodgkin's lymphoma (NHL)
J Joyce, MW Schuster, B McCook, F Torok… - Journal of Clinical …, 2005 - ascopubs.org
6669 Background: Yttrium 90 ibritumomab tiuxetan (90Y IT [Zevalin]) is approved for the
treatment of relapsed or refractory B-cell NHL achieving durable responses in heavily …
treatment of relapsed or refractory B-cell NHL achieving durable responses in heavily …
Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients with Prior Myeloablative Chemotherapy
SA Jacobs, N Vidnovic, J Joyce, B McCook, F Torok… - Clinical cancer …, 2005 - AACR
Purpose: Targeted radioimmunotherapy with yttrium-90 (90Y)–labeled ibritumomab tiuxetan
(Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of …
(Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of …
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma
Purpose: Radioimmunotherapy (RIT) with yttrium-90 (90Y)-labeled anti-CD20 antibody (90Y
ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a …
ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a …
Phase I Study of a Modified Regimen of 90Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma
C Vaklavas, RF Meredith, S Shen, SJ Knox… - Cancer Biotherapy …, 2013 - liebertpub.com
Radioimmunotherapy capitalizes on the radiosensitivity of non-Hodgkin lymphoma (NHL)
and the targeted nature of monoclonal antibodies. In an attempt to reverse bone marrow …
and the targeted nature of monoclonal antibodies. In an attempt to reverse bone marrow …
High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous …
A Nademanee, SJ Forman, A Molina… - Journal of Clinical …, 2004 - ascopubs.org
6504 Background: A phase I/II trial investigated whether high-dose ibritumomab tiuxetan
(Zevalin [Z]) can be safely combined with high-dose VP-16 40–60 mg/kg and CY 100 mg/kg …
(Zevalin [Z]) can be safely combined with high-dose VP-16 40–60 mg/kg and CY 100 mg/kg …
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell …
We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with
high-dose etoposide (VP-16) 40 to 60 mg/kg (day-4) and cyclophosphamide 100 mg/kg (day …
high-dose etoposide (VP-16) 40 to 60 mg/kg (day-4) and cyclophosphamide 100 mg/kg (day …
Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non …
IW Flinn, BS Kahl, EC Frey, JA Bianco… - Journal of Clinical …, 2006 - ascopubs.org
7535 Background: 90YIT is an effective agent for patients with lymphoma. Unfortunately,
dose escalation is limited by hematopoetic toxicity. In order to determine the non …
dose escalation is limited by hematopoetic toxicity. In order to determine the non …